On June 17, the Institut reConnect, the Brain&Mind biocluster and the Paris Public Hospital Network (AP-HP) inaugurated the NULISA™ ultra-high sensitivity clinical proteomics platform at Lariboisière – Fernand-Widal Hospital AP-HP, during an event attended by Nicolas Revel, CEO of AP-HP, Claire Paquet, a neurologist at the hospital and Scientific Director of the Institut reConnect (a foundation hosted by the Institut Pasteur), and Alexis Génin, CEO of Brain&Mind. The entire Brain&Mind community, which includes the reConnect University Hospital Institute and the AP-HP, can now make use of this state-of-the-art technology, which offers unprecedented sensitivity for characterizing the profiles of circulating biomarkers in patients with neurological or psychiatric disorders or sensory impairments.

Find out more (in French, English version coming soon)